These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
273 related items for PubMed ID: 25758472
1. ATON: results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis. Sergott RC, Bennett JL, Rieckmann P, Montalban X, Mikol D, Freudensprung U, Plitz T, van Beek J, ATON Trial Group. J Neurol Sci; 2015 Apr 15; 351(1-2):174-178. PubMed ID: 25758472 [Abstract] [Full Text] [Related]
2. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J, ATAMS Study Group. Lancet Neurol; 2014 Apr 15; 13(4):353-63. PubMed ID: 24613349 [Abstract] [Full Text] [Related]
3. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P, IMSVISUAL consortium. Lancet Neurol; 2016 May 15; 15(6):574-84. PubMed ID: 27011339 [Abstract] [Full Text] [Related]
4. [Retinal atrophy using optical coherence tomography (OCT) in 15 patients with multiple sclerosis and comparison with healthy subjects]. Jeanjean L, Castelnovo G, Carlander B, Villain M, Mura F, Dupeyron G, Labauge P. Rev Neurol (Paris); 2008 Nov 15; 164(11):927-34. PubMed ID: 18808761 [Abstract] [Full Text] [Related]
5. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J. Arthritis Rheum; 2011 Jul 15; 63(7):1782-92. PubMed ID: 21452294 [Abstract] [Full Text] [Related]
6. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Arthritis Rheum; 2007 Dec 15; 56(12):4142-50. PubMed ID: 18050206 [Abstract] [Full Text] [Related]
7. Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography. Costello F, Hodge W, Pan YI, Eggenberger E, Coupland S, Kardon RH. Mult Scler; 2008 Aug 15; 14(7):893-905. PubMed ID: 18573837 [Abstract] [Full Text] [Related]
8. Treatment with atacicept enhances neuronal cell death in a rat model of optic neuritis. Kretzschmar B, Hein K, Moinfar Z, Könnecke B, Sättler MB, Hess H, Weissert R, Bähr M. J Neuroimmunol; 2014 Mar 15; 268(1-2):58-63. PubMed ID: 24485150 [Abstract] [Full Text] [Related]
9. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Henderson AP, Altmann DR, Trip AS, Kallis C, Jones SJ, Schlottmann PG, Garway-Heath DF, Plant GT, Miller DH. Brain; 2010 Sep 15; 133(9):2592-602. PubMed ID: 20566483 [Abstract] [Full Text] [Related]
10. Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial. van Vollenhoven RF, Wax S, Li Y, Tak PP. Arthritis Rheumatol; 2015 Nov 15; 67(11):2828-36. PubMed ID: 26137975 [Abstract] [Full Text] [Related]
11. Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol. Diem R, Molnar F, Beisse F, Gross N, Drüschler K, Heinrich SP, Joachimsen L, Rauer S, Pielen A, Sühs KW, Linker RA, Huchzermeyer C, Albrecht P, Hassenstein A, Aktas O, Guthoff T, Tonagel F, Kernstock C, Hartmann K, Kümpfel T, Hein K, van Oterendorp C, Grotejohann B, Ihorst G, Maurer J, Müller M, Volkmann M, Wildemann B, Platten M, Wick W, Heesen C, Schiefer U, Wolf S, Lagrèze WA. BMJ Open; 2016 Mar 01; 6(3):e010956. PubMed ID: 26932144 [Abstract] [Full Text] [Related]
12. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Sühs KW, Hein K, Sättler MB, Görlitz A, Ciupka C, Scholz K, Käsmann-Kellner B, Papanagiotou P, Schäffler N, Restemeyer C, Bittersohl D, Hassenstein A, Seitz B, Reith W, Fassbender K, Hilgers R, Heesen C, Bähr M, Diem R. Ann Neurol; 2012 Aug 01; 72(2):199-210. PubMed ID: 22926853 [Abstract] [Full Text] [Related]
13. Analysis of macular and nerve fiber layer thickness in multiple sclerosis patients according to severity level and optic neuritis episodes. Soler García A, Padilla Parrado F, Figueroa-Ortiz LC, González Gómez A, García-Ben A, García-Ben E, García-Campos JM. Neurologia; 2016 Aug 01; 31(6):379-88. PubMed ID: 25529178 [Abstract] [Full Text] [Related]
14. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Raftopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, Paling D, Altmann DR, Yiannakas MC, Malladi P, Sheridan R, Sarrigiannis PG, Hoggard N, Koltzenburg M, Gandini Wheeler-Kingshott CA, Schmierer K, Giovannoni G, Miller DH, Kapoor R. Lancet Neurol; 2016 Mar 01; 15(3):259-69. PubMed ID: 26822749 [Abstract] [Full Text] [Related]
15. A prospective cohort study of vitamin D in optic neuritis recovery. Burton JM, Eliasziw M, Trufyn J, Tung C, Carter G, Costello F. Mult Scler; 2017 Jan 01; 23(1):82-93. PubMed ID: 27037181 [Abstract] [Full Text] [Related]
16. Changes in oxygen saturation and the retinal nerve fibre layer in patients with optic neuritis - a pilot study. Svrčinová T, Mareš J, Chrapek O, Šínová I, Rybariková M, Otruba P, Kaňovský P, Šín M. Acta Ophthalmol; 2018 May 01; 96(3):e309-e314. PubMed ID: 29090843 [Abstract] [Full Text] [Related]
17. Color-code agreement among stratus, cirrus, and spectralis optical coherence tomography in relapsing-remitting multiple sclerosis with and without prior optic neuritis. Rebolleda G, González-López JJ, Muñoz-Negrete FJ, Oblanca N, Costa-Frossard L, Álvarez-Cermeño JC. Am J Ophthalmol; 2013 May 01; 155(5):890-7. PubMed ID: 23398979 [Abstract] [Full Text] [Related]
18. Reduced retinal nerve fiber layer and macular thickness in patients with multiple sclerosis with no history of optic neuritis identified by the use of spectral domain high-definition optical coherence tomography. Fjeldstad C, Bemben M, Pardo G. J Clin Neurosci; 2011 Nov 01; 18(11):1469-72. PubMed ID: 21917458 [Abstract] [Full Text] [Related]
19. Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. Zimmermann H, Freing A, Kaufhold F, Gaede G, Bohn E, Bock M, Oberwahrenbrock T, Young KL, Dörr J, Wuerfel JT, Schippling S, Paul F, Brandt AU. Mult Scler; 2013 Apr 01; 19(4):443-50. PubMed ID: 22936335 [Abstract] [Full Text] [Related]
20. A double-blind, placebo-controlled trial of adding erythropoietin to intravenous methylprednisolone for the treatment of unilateral acute optic neuritis of unknown or demyelinative origin. Shayegannejad V, Shahzamani S, Dehghani A, Dast Borhan Z, Rahimi M, Mirmohammadsadeghi A. Graefes Arch Clin Exp Ophthalmol; 2015 May 01; 253(5):797-801. PubMed ID: 25605544 [Abstract] [Full Text] [Related] Page: [Next] [New Search]